Last reviewed · How we verify

Single dose of HDM1002 on Day 1

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

Single dose of HDM1002 on Day 1 is a Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic nameSingle dose of HDM1002 on Day 1
SponsorHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Single dose of HDM1002 on Day 1

What is Single dose of HDM1002 on Day 1?

Single dose of HDM1002 on Day 1 is a Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd..

Who makes Single dose of HDM1002 on Day 1?

Single dose of HDM1002 on Day 1 is developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (see full Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. pipeline at /company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd).

What development phase is Single dose of HDM1002 on Day 1 in?

Single dose of HDM1002 on Day 1 is in Phase 1.

Related